Objective: to construct and validate an educational booklet on high dose rate gynecological brachytherapy (HDR) for women with gynecologic cancer.
Methods: a methodological study, with the construction and validity of a booklet based on the Doak, Doak and Root theoretical-methodological framework. Content and appearance validity was guided by the Delphi technique, by 11 judges, selected using Jasper's criteria. Afterwards, clinical validity was carried out with the target population.
Results: the booklet, built from evidence from an integrative review, validated with judges, obtained an overall CVI of 0.98. After clinical validity with 27 women, it presents 24 sheets with illustrations produced by a graphic designer, subdivided into topics: gynecological system anatomy and gynecological cancer epidemiology, gynecological brachytherapy definition, therapeutic steps, approach to side effects and management, and two pages for notes.
Conclusions: the booklet has validity for use in HDR gynecological brachytherapy treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10103639 | PMC |
| http://dx.doi.org/10.1590/0034-7167-2022-0232 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Real-world outcomes of PARP inhibitor maintenance in advanced ovarian cancer: a focus on disease patterns and treatment modalities at recurrence.
ESMO Open
January 2025
Department of Woman's and Child health and Public Health Sciences, Gynecologic Oncology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; Catholic University of the Sacred Heart, Rome, Italy. Electronic address:
Background: The utilization of poly-ADP-ribose polymerase (PARP) inhibitors (PARPi) as a first-line maintenance therapy for advanced ovarian cancer has increased significantly, with ∼80% of patients potentially eligible. This expansion has led to a rise in the population experiencing platinum-sensitive recurrence, yet data on first recurrence during PARPi are limited. This real-world study from a high-volume referral center aims to elucidate recurrence rates, disease distribution, and treatment modalities at the time of progression in PARPi-treated patients.
View Article and Find Full Text PDFAdjuvant Therapy in Early Uterine Serous Carcinoma.
Am J Epidemiol
January 2025
Division of Gynecologic Oncology, UPMC Magee-Womens Hospital, Pittsburgh PA, USA.
Objective: Uterine serous carcinoma (USC) is a rare diagnosis but associated with high mortality. There is limited data to guide adjuvant treatment decisions in early stage disease. The purpose of this study is to evaluate the impact of adjuvant therapy on recurrence-free survival (RFS) and overall survival (OS) in early stage USC.
View Article and Find Full Text PDFLearning curve and proficiency assessment for gynecological brachytherapy amongst radiation oncology trainees in India: Results from a prospective study.
Brachytherapy
January 2025
Department of Radiation Oncology and Medical Physics, Advanced Centre for Treatment Research and Education in Cancer, Tata Memorial Centre, Homi Bhabha National Institute, Navi Mumbai, India. Electronic address:
Purpose: The quality of cervical cancer intracavitary brachytherapy (ICBT) depends on the training and experience of the radiation oncologist (RO). The present study was performed to establish primary learning curve for ICBT.
Materials And Methods: Forty-three skill parameters were identified for performing ICBT and were included for Brachytherapy Proficiency Assessment and Scoring System (Brachy-PASS) questionnaire.
The clinical application of in vivo dosimetry for gynaecological brachytherapy: A scoping review.
Tech Innov Patient Support Radiat Oncol
March 2025
Mount Vernon Cancer Centre, Northwood, United Kingdom.
Brachytherapy is a key treatment for gynaecological malignancies, delivering high doses to the tumour volume whilst sparing nearby normal tissues due to its steep dose gradient. Accuracy is imperative as small shifts can lead to clinically significant under- or over-dosing of the target volume or organs at risk (OARs), respectively. Independent verification of dose delivered during brachytherapy is not routinely performed but it is important to identify gross errors and define action thresholds to guide inter-fraction treatment decisions.
View Article and Find Full Text PDFAnesthetic Considerations for Gynecologic HDR Brachytherapy.
Pract Radiat Oncol
January 2025
Department of Anesthesiology, Emory University.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!